<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03734783</url>
  </required_header>
  <id_info>
    <org_study_id>16ZR1400400</org_study_id>
    <nct_id>NCT03734783</nct_id>
  </id_info>
  <brief_title>IL-35+Breg/Il-35 Effect on T Cell Immune in Patients With CHB</brief_title>
  <official_title>Regulate Effect of Il-35 Secreting Breg Cells on Tcells and on Diseases Progression in Patients With CHB</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Changhai Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Changhai Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators observed the level of IL-35 secreting B regulatory (IL-35+Bregs) cells in
      peripheral blood cells in patients with chronic hepatitis B, and analysed the relationship
      between the IL-35+Bregs level and disease stage, and Th1 and Th2 cells level.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Regulatory B cells (Bregs) are involved in the immune tolerance process through multiple
      pathways and Bregs are involved in the process of chronic HBV infection.

      Here the investigators intended to investigate the regulating role and the mechanism of CD19+
      IL-35+ cells on host T cell immune during chronic HBV infection by using in vitro cell
      sorting, B cell differentiation induction, Transwell cell co-culture system and other
      methods.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 1, 2017</start_date>
  <completion_date type="Actual">November 15, 2019</completion_date>
  <primary_completion_date type="Actual">November 15, 2019</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <target_duration>1 Day</target_duration>
  <primary_outcome>
    <measure>IL-35+Bregs level</measure>
    <time_frame>ENROLLED DAY</time_frame>
    <description>IL-35 secreting regulatory B cells level in patients with CHB</description>
  </primary_outcome>
  <primary_outcome>
    <measure>IL-35+Bregs regulatory effect</measure>
    <time_frame>enrolled day</time_frame>
    <description>regulatory effect of IL-35+Bregs on T cell immune</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>IL-35+Bregs phenotype</measure>
    <time_frame>enrolled day</time_frame>
    <description>the main phenotype of IL-35 secreting Bregs</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">55</enrollment>
  <condition>Chronic Hepatitis b</condition>
  <arm_group>
    <arm_group_label>Patients</arm_group_label>
    <description>HBsAg positive more than 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>health control</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with chronic hepatitis B infection
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of chronic hepatitis B virus infection

          -  17＜age＜70

          -  Can read, understand and sign patients informed consent

        Exclusion Criteria:

          -  Co-infection with HCV,HIV,HDV etc.

          -  Have malignancy

          -  Have uncontrollable extra-hepatic disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>17 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Changhai hospital</name>
      <address>
        <city>Shanghai</city>
        <zip>200433</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>October 31, 2018</study_first_submitted>
  <study_first_submitted_qc>November 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 8, 2018</study_first_posted>
  <last_update_submitted>November 15, 2019</last_update_submitted>
  <last_update_submitted_qc>November 15, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Changhai Hospital</investigator_affiliation>
    <investigator_full_name>LiangXS</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>chronic hepatitis B</keyword>
  <keyword>regulating B cells</keyword>
  <keyword>T help 17 cells</keyword>
  <keyword>Interleukin 35</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

